Dr. Yue Zhang, MD

Dr. Zhang practices at Virginia Oncology Associates in Norfolk, Virginia.

Dr. Zhang's NPI, 1881906311, was assigned on July 13, 2010. Dr. Zhang holds Virginia license 0101269777.

Dr. Zhang's primary practice is Virginia Oncology Associates, at 6251 E Virginia Beach Blvd, Norfolk, VA 23502 in Norfolk City. The practice phone is (757) 466-8683.

Dr. Zhang's primary practice is Virginia Oncology Associates in Norfolk, Virginia. Dr. Zhang is also affiliated with Sentara Norfolk General Hospital. The medical group on file is Virginia Oncology Associates. Dmand AI also links Dr. Zhang to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zhang practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Zhang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Zhang's licenses on file in 2 states: Virginia and New York.

CMS data shows 128,620 Medicare services from Dr. Zhang across 70 procedure codes in 2024, for 667 Medicare patients. Medicare paid $2,154,394 for them.

CMS counts 667 Medicare patients who saw Dr. Zhang in 2024. The largest group is 65 to 74, with 285 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zhang's median patient age at 65, with 55% women.

In 2024, Dr. Zhang wrote 650 Medicare Part D claims for 133 patients. 72% of them were for generic drugs. CMS names the drug for 416 of them, across 20 drugs with 11 or more claims each, at $2,139,724 in total drug cost. In 2023, CMS named 375 claims across 17 drugs.

Dr. Zhang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zhang as offering telehealth.

Dmand AI links 4 papers to Dr. Zhang, published from 2022 to 2025. 2023 was the busiest year, with 2. The most frequent topics are Skin Neoplasms. Dr. Zhang's most frequent co-author is Tessa Marie Lewitt.

CMS Open Payments shows 171 general payments to Dr. Zhang from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 36% of the total. Merck Sharp & Dohme Corporation paid the most, $41,027. It also lists 2 research payments totaling $37 in 2018.